Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson's disease

Next Previous
Trial Profile

A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson's disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Annovis Bio

    • Most Recent Events

    • 24 Jan 2024 According to an Annovis Bio media release, the company announced a postponement in the Phase III study data release for buntanetap in Parkinsons Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
    • 12 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 05 Dec 2023 According to an Annovis Bio media release, the company announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinsons disease (PD).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top